검색어 : 통합검색[Fennema Owen R.]
-
21
-
Neural responses to facial emotions and subsequent clinical outcomes in difficult-to-treat depression
-
Fennema, Diede;
Barker, Gareth J.;
O'Daly, Owen;
Duan, Suqian;
Godlewska, Beata R.;
Goldsmith, Kimberley;
Young, Allan H.;
Moll, Jorge;
Zahn, Roland;
;
(Psychological medicine,
v.54,
2024,
pp.3044-3052)
-
22
-
MA12.07 Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSA
-
Nguyen, D.;
Besse, B.;
Cho, B.C.;
Lee, S.-H.;
Lee, K.H.;
Lu, S.;
Cheng, Y.;
Yao, Y.;
Girard, N.;
Lin, C.-C.;
Felip, E.;
Aguilar, A.;
Charoentum, C.;
Cruz, F.J.S.M.;
Majem, M.;
Lim, C.S.;
Akamatsu, H.;
Hayashi, H.;
Yang, J.C.-H.;
Kowalyszyn, R.;
Tiscoski, K.;
Franke, F.;
Ponomarenko, D.;
Arslan, C.;
Forster, M.;
Urban, D.;
Misch, D.;
Delmonte, A.;
Montes, L.V.G.;
Gadgeel, S.M.;
Cruz-Correa, M.;
Peguero, J.;
Rousey, S.;
Gaffar, Y.;
Owen, S.;
Schuchard, J.;
Diels, J.;
Sermon, J.;
Sun, T.;
Ennis, M.;
Fennema, E.;
Daksh, M.;
Sethi, S.;
Bauml, J.M.;
Campelo, M.R. Garcia;
;
(Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
v.19,
2024,
pp.S103-S104)
-
23
-
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
-
Felip, E.;
Cho, B.C.;
Gutié
rrez, V.;
Alip, A.;
Besse, B.;
Lu, S.;
Spira, A.I.;
Girard, N.;
Califano, R.;
Gadgeel, S.M.;
Yang, J.C.-H.;
Yamamoto, S.;
Azuma, K.;
Kim, Y.J.;
Lee, K.-H.;
Danchaivijitr, P.;
Ferreira, C.G.;
Cheng, Y.;
Sendur, M.A.N.;
Chang, G.-C.;
Wang, C.-C.;
Prabhash, K.;
Shinno, Y.;
Stroyakovskiy, D.;
Paz-Ares, L.;
Rodriguez-Cid, J.R.;
Martin, C.;
Campelo, M.R.G.;
Hayashi, H.;
Nguyen, D.;
Tomasini, P.;
Gottfried, M.;
Dooms, C.;
Passaro, A.;
Schuler, M.;
Gelatti, A.C.Z.;
Owen, S.;
Perdrizet, K.;
Ou, S.-H.I.;
Curtin, J.C.;
Zhang, J.;
Gormley, M.;
Sun, T.;
Panchal, A.;
Ennis, M.;
Fennema, E.;
Daksh, M.;
Sethi, S.;
Bauml, J.M.;
Lee, S.-H.;
;
(Annals of oncology : official journal of the European Society for Medical Oncology,
v.35,
2024,
pp.805-816)